Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Iovance Biotherapeutics, Inc. 0JDK.L
$7.54
На 18:02, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
956206615.00000000
-
week52high
14.58
-
week52low
5.29
-
Revenue
-
P/E TTM
0
-
Beta
0.20276800
-
EPS
-2.30000000
-
Last Dividend
0.28500000
-
Next Earnings Date
09 мая 2023 г. в 20:00
Описание компании
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Свежие комментарии
Свежие комментарии